

Appl. No. : 01,797
Filed : July 23, 1998

B4
cont

pharmaceutically acceptable carrier to reduce the expression and/or effects resulting from expression of said polynucleotide encoding or said peptide, said inhibitor being directed against [said]the isolated polynuceotide, or [an] isolated peptide of Claim 35[, or a receptor or receptors of said isolated peptide].

REMARKS

Applicants acknowledge receipt of the communication mailed from the Patent and Trademark Office on December 22, 1999 (Paper No. 6). Applicants have elected for initial prosecution Group I Claims 35-42 and 47 as required in the Restriction Requirement of December 22, 1999. Claims 43-46 and 53-56 are cancelled as being drawn to a non-elected invention. This election is made without traverse.

Conclusion

Should there be any questions concerning this application, the Examiner is invited to contact the undersigned attorney at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 24 Jan. 2000

By: Daniel Altman
Daniel E. Altman
Registration No. 34,115
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

H:\DOCS\VAHV\AH-1937.DOC
012000